UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Why Is Amyloid-β PET Requested After Performing Cerebrospinal Fluid Biomarkers?

Reimand, J; Groot, C; Teunissen, CE; Windhorst, AD; Boellaard, R; Barkhof, F; Nazarenko, S; ... Bouwman, F; + view all (2019) Why Is Amyloid-β PET Requested After Performing Cerebrospinal Fluid Biomarkers? Journal of Alzheimer's Disease 10.3233/JAD-190836. (In press). Green open access

[thumbnail of Reimand - Why is amyloid PET requested after performing CSF - JAD accepted version.pdf]
Preview
Text
Reimand - Why is amyloid PET requested after performing CSF - JAD accepted version.pdf - Accepted Version

Download (1MB) | Preview

Abstract

BACKGROUND: Amyloid-β PET and cerebrospinal fluid (CSF) Aβ42 are considered interchangeable for clinical diagnosis of Alzheimer's disease. OBJECTIVE: To explore the clinical reasoning for requesting additional amyloid-β PET after performing CSF biomarkers. METHODS: We retrospectively identified 72 memory clinic patients who underwent amyloid-β PET after CSF biomarkers analysis for clinical diagnostic evaluation between 2011 and 2019. We performed patient chart reviews to identify factors which led to additional amyloid-β PET. Additionally, we assessed accordance with appropriate-use-criteria (AUC) for amyloid-β PET. RESULTS: Mean patient age was 62.0 (SD = 8.1) and mean Mini-Mental State Exam score was 23.6 (SD = 3.8). CSF analysis conflicting with the clinical diagnosis was the most frequent reason for requesting an amyloid-β PET scan (n = 53, 74%), followed by incongruent MRI (n = 16, 22%), unusual clinical presentation (n = 11, 15%) and young age (n = 8, 11%). An amyloid-β PET scan was rarely (n = 5, 7%) requested in patients with a CSF Aβ+/tau+ status. Fifteen (47%) patients with a post-PET diagnosis of AD had a predominantly non-amnestic presentation. In n = 11 (15%) cases, the reason that the clinician requested amyloid-β was not covered by AUC. This happened most often (n = 7) when previous CSF analysis did not support current clinical diagnosis, which led to requesting amyloid-β PET. CONCLUSION: In this single-center study, the main reason for requesting an amyloid-β PET scan after performing CSF biomarkers was the occurrence of a mismatch between the primary clinical diagnosis and CSF Aβ/tau results.

Type: Article
Title: Why Is Amyloid-β PET Requested After Performing Cerebrospinal Fluid Biomarkers?
Location: Netherlands
Open access status: An open access version is available from UCL Discovery
DOI: 10.3233/JAD-190836
Publisher version: https://doi.org/10.3233/JAD-190836
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Alzheimer’s disease, amyloid, cerebrospinal fluid, positron emission tomography, tau proteins
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Brain Repair and Rehabilitation
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10087988
Downloads since deposit
177Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item